Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis

L. Sanchez-Urdazpal, A. J. Czaja, B. Van Hoek, R. A F Krom, R. H. Wiesner

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

To identify prognostic features and to define the role of liver transplantation in severe autoimmune chronic active hepatitis, findings before and after corticosteroid therapy in 111 patients were correlated with outcome and compared with the findings in 24 patients who had been selected independently for liver transplantation. Patients whose condition deteriorated during corticosteroid treatment were younger (32 ± 3 yr vs. 43 ± 2 yr; p < 0.02) than those who experienced remission, but no individual features predicted outcome. Patients in whom therapy failed required longer durations of continuous treatment than did those who experienced remission (60 ± 14 mo vs. 20 ± 12 mo; p = 0.001). Of 13 patients who did not experience remission within 4 yr, 9 (69%) ultimately deteriorated. Ascites developed more often in those patients whose therapy failed and who died of liver failure than in counterparts who survived (86% vs. 33%). Patients undergoing transplantation were similar to those whose treatment failed, but they died less frequently (8% vs. 56%, p < 0.01). Indeed, the 5-yr survival rate after transplantation was comparable to that of patients who had entered remission (92% vs. 100%). Successive biopsy samples failed to disclose recurrent autoimmune hepatitis after transplantation. Human leukocyte antigens A1, B8 occurred more commonly in patients in whom treatment failed or who underwent transplantation (70% vs. 41%, p < 0.05). We conclude that failure to achieve remission within 4 yr and the human leukocyte antigen A1, B8 phenotype are associated with poor prognosis. Manifestations of liver decompensation, such as ascites, in patients who have been unable to experience remission justify consideration of transplantation. Transplantation improves the survival of patients with features of treatment failure, and it is not associated with recurrent disease.

Original languageEnglish (US)
Pages (from-to)215-221
Number of pages7
JournalHepatology
Volume15
Issue number2
StatePublished - 1992

Fingerprint

Autoimmune Hepatitis
Chronic Hepatitis
Liver Transplantation
Adrenal Cortex Hormones
Transplantation
HLA Antigens
Ascites
Therapeutics
Liver Failure
Treatment Failure
Survival Rate

ASJC Scopus subject areas

  • Hepatology

Cite this

Sanchez-Urdazpal, L., Czaja, A. J., Van Hoek, B., Krom, R. A. F., & Wiesner, R. H. (1992). Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology, 15(2), 215-221.

Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. / Sanchez-Urdazpal, L.; Czaja, A. J.; Van Hoek, B.; Krom, R. A F; Wiesner, R. H.

In: Hepatology, Vol. 15, No. 2, 1992, p. 215-221.

Research output: Contribution to journalArticle

Sanchez-Urdazpal, L, Czaja, AJ, Van Hoek, B, Krom, RAF & Wiesner, RH 1992, 'Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis', Hepatology, vol. 15, no. 2, pp. 215-221.
Sanchez-Urdazpal, L. ; Czaja, A. J. ; Van Hoek, B. ; Krom, R. A F ; Wiesner, R. H. / Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. In: Hepatology. 1992 ; Vol. 15, No. 2. pp. 215-221.
@article{3ea1d3e92c204391b6b801e68fc8d528,
title = "Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis",
abstract = "To identify prognostic features and to define the role of liver transplantation in severe autoimmune chronic active hepatitis, findings before and after corticosteroid therapy in 111 patients were correlated with outcome and compared with the findings in 24 patients who had been selected independently for liver transplantation. Patients whose condition deteriorated during corticosteroid treatment were younger (32 ± 3 yr vs. 43 ± 2 yr; p < 0.02) than those who experienced remission, but no individual features predicted outcome. Patients in whom therapy failed required longer durations of continuous treatment than did those who experienced remission (60 ± 14 mo vs. 20 ± 12 mo; p = 0.001). Of 13 patients who did not experience remission within 4 yr, 9 (69{\%}) ultimately deteriorated. Ascites developed more often in those patients whose therapy failed and who died of liver failure than in counterparts who survived (86{\%} vs. 33{\%}). Patients undergoing transplantation were similar to those whose treatment failed, but they died less frequently (8{\%} vs. 56{\%}, p < 0.01). Indeed, the 5-yr survival rate after transplantation was comparable to that of patients who had entered remission (92{\%} vs. 100{\%}). Successive biopsy samples failed to disclose recurrent autoimmune hepatitis after transplantation. Human leukocyte antigens A1, B8 occurred more commonly in patients in whom treatment failed or who underwent transplantation (70{\%} vs. 41{\%}, p < 0.05). We conclude that failure to achieve remission within 4 yr and the human leukocyte antigen A1, B8 phenotype are associated with poor prognosis. Manifestations of liver decompensation, such as ascites, in patients who have been unable to experience remission justify consideration of transplantation. Transplantation improves the survival of patients with features of treatment failure, and it is not associated with recurrent disease.",
author = "L. Sanchez-Urdazpal and Czaja, {A. J.} and {Van Hoek}, B. and Krom, {R. A F} and Wiesner, {R. H.}",
year = "1992",
language = "English (US)",
volume = "15",
pages = "215--221",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis

AU - Sanchez-Urdazpal, L.

AU - Czaja, A. J.

AU - Van Hoek, B.

AU - Krom, R. A F

AU - Wiesner, R. H.

PY - 1992

Y1 - 1992

N2 - To identify prognostic features and to define the role of liver transplantation in severe autoimmune chronic active hepatitis, findings before and after corticosteroid therapy in 111 patients were correlated with outcome and compared with the findings in 24 patients who had been selected independently for liver transplantation. Patients whose condition deteriorated during corticosteroid treatment were younger (32 ± 3 yr vs. 43 ± 2 yr; p < 0.02) than those who experienced remission, but no individual features predicted outcome. Patients in whom therapy failed required longer durations of continuous treatment than did those who experienced remission (60 ± 14 mo vs. 20 ± 12 mo; p = 0.001). Of 13 patients who did not experience remission within 4 yr, 9 (69%) ultimately deteriorated. Ascites developed more often in those patients whose therapy failed and who died of liver failure than in counterparts who survived (86% vs. 33%). Patients undergoing transplantation were similar to those whose treatment failed, but they died less frequently (8% vs. 56%, p < 0.01). Indeed, the 5-yr survival rate after transplantation was comparable to that of patients who had entered remission (92% vs. 100%). Successive biopsy samples failed to disclose recurrent autoimmune hepatitis after transplantation. Human leukocyte antigens A1, B8 occurred more commonly in patients in whom treatment failed or who underwent transplantation (70% vs. 41%, p < 0.05). We conclude that failure to achieve remission within 4 yr and the human leukocyte antigen A1, B8 phenotype are associated with poor prognosis. Manifestations of liver decompensation, such as ascites, in patients who have been unable to experience remission justify consideration of transplantation. Transplantation improves the survival of patients with features of treatment failure, and it is not associated with recurrent disease.

AB - To identify prognostic features and to define the role of liver transplantation in severe autoimmune chronic active hepatitis, findings before and after corticosteroid therapy in 111 patients were correlated with outcome and compared with the findings in 24 patients who had been selected independently for liver transplantation. Patients whose condition deteriorated during corticosteroid treatment were younger (32 ± 3 yr vs. 43 ± 2 yr; p < 0.02) than those who experienced remission, but no individual features predicted outcome. Patients in whom therapy failed required longer durations of continuous treatment than did those who experienced remission (60 ± 14 mo vs. 20 ± 12 mo; p = 0.001). Of 13 patients who did not experience remission within 4 yr, 9 (69%) ultimately deteriorated. Ascites developed more often in those patients whose therapy failed and who died of liver failure than in counterparts who survived (86% vs. 33%). Patients undergoing transplantation were similar to those whose treatment failed, but they died less frequently (8% vs. 56%, p < 0.01). Indeed, the 5-yr survival rate after transplantation was comparable to that of patients who had entered remission (92% vs. 100%). Successive biopsy samples failed to disclose recurrent autoimmune hepatitis after transplantation. Human leukocyte antigens A1, B8 occurred more commonly in patients in whom treatment failed or who underwent transplantation (70% vs. 41%, p < 0.05). We conclude that failure to achieve remission within 4 yr and the human leukocyte antigen A1, B8 phenotype are associated with poor prognosis. Manifestations of liver decompensation, such as ascites, in patients who have been unable to experience remission justify consideration of transplantation. Transplantation improves the survival of patients with features of treatment failure, and it is not associated with recurrent disease.

UR - http://www.scopus.com/inward/record.url?scp=0026571063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026571063&partnerID=8YFLogxK

M3 - Article

C2 - 1735524

AN - SCOPUS:0026571063

VL - 15

SP - 215

EP - 221

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -